A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors.
CNS tumors
adult glioma
cannabis
clinical outcomes
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
ppublish
Résumé
Primary CNS tumors constitute a heterogeneous group of neoplasms that share a considerable morbidity and mortality rate. To help control tumor growth and clinical outcomes (overall survival, progression-free survival, quality of life) symptoms, patients often resort to alternative therapies, including the use of cannabis. Despite rapidly growing popularity, cannabis and its impact on patients with primary malignant CNS tumors is understudied. To shed light on the lack of scientific evidence in this field, in November 2018 we conducted a search and examination of cannabis in neuro-oncology in major journal databases and bibliographies of selected articles, and through abstracts of annual meetings using prespecified criteria in line with the Cochrane Collaboration guidelines. We identified 45 publications, of which 9 were selected. Five studies were included. Publication dates ranged from 2004 to 2018 and included varying histologies of primary brain tumors. The average survival at 1 year was 56.09% (95% CI: 48.28-63.9). There was no difference in risk ratio (RR) for death at 1 year between groups (RR: 1.069 [95% CI: 0.139-8.25]). We found strong evidence of heterogeneity (Q = 74.0%; There was limited moderate-quality evidence that supports the use of cannabinoids as adjuvant to the standard of care in the treatment of brain and CNS tumors. There was very low-quality evidence suggesting that cannabinoids were associated with adult-onset gliomas. Further prospective clinical trials are necessary to adequately evaluate the impact of cannabinoids on CNS tumors, specifically on survival and quality of life.
Sections du résumé
BACKGROUND
BACKGROUND
Primary CNS tumors constitute a heterogeneous group of neoplasms that share a considerable morbidity and mortality rate. To help control tumor growth and clinical outcomes (overall survival, progression-free survival, quality of life) symptoms, patients often resort to alternative therapies, including the use of cannabis. Despite rapidly growing popularity, cannabis and its impact on patients with primary malignant CNS tumors is understudied.
METHODS
METHODS
To shed light on the lack of scientific evidence in this field, in November 2018 we conducted a search and examination of cannabis in neuro-oncology in major journal databases and bibliographies of selected articles, and through abstracts of annual meetings using prespecified criteria in line with the Cochrane Collaboration guidelines.
RESULTS
RESULTS
We identified 45 publications, of which 9 were selected. Five studies were included. Publication dates ranged from 2004 to 2018 and included varying histologies of primary brain tumors. The average survival at 1 year was 56.09% (95% CI: 48.28-63.9). There was no difference in risk ratio (RR) for death at 1 year between groups (RR: 1.069 [95% CI: 0.139-8.25]). We found strong evidence of heterogeneity (Q = 74.0%;
CONCLUSIONS
CONCLUSIONS
There was limited moderate-quality evidence that supports the use of cannabinoids as adjuvant to the standard of care in the treatment of brain and CNS tumors. There was very low-quality evidence suggesting that cannabinoids were associated with adult-onset gliomas. Further prospective clinical trials are necessary to adequately evaluate the impact of cannabinoids on CNS tumors, specifically on survival and quality of life.
Identifiants
pubmed: 32765889
doi: 10.1093/nop/npaa013
pii: npaa013
pmc: PMC7393278
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
376-383Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Clin Oncol. 2007 Dec 20;25(36):5723-30
pubmed: 18089866
Cannabis Cannabinoid Res. 2016 Jun 01;1(1):131-138
pubmed: 28861489
Eur J Cancer. 2001 Feb;37(3):332-9
pubmed: 11239754
J Pain Symptom Manage. 2018 Feb;55(2):179-188.e1
pubmed: 28923526
J Clin Oncol. 2006 Jul 20;24(21):3394-400
pubmed: 16849753
J Neurooncol. 2004 May;68(1):57-69
pubmed: 15174522
Mol Neurobiol. 2007 Aug;36(1):60-7
pubmed: 17952650
Eur J Intern Med. 2018 Mar;49:37-43
pubmed: 29482741
Oncology (Williston Park). 2016 May;30(5):397-404
pubmed: 27188670
Int J Drug Policy. 2017 Apr;42:30-35
pubmed: 28189912
Res Social Adm Pharm. 2016 Jul-Aug;12(4):638-54
pubmed: 26443472
Brain. 2007 Oct;130(Pt 10):2596-606
pubmed: 17785346
J Clin Oncol. 2001 Oct 15;19(20):4037-47
pubmed: 11600605
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Annu Rev Psychol. 2013;64:21-47
pubmed: 22804774
J Natl Compr Canc Netw. 2011 Apr;9(4):352-400
pubmed: 21464144
Chem Biodivers. 2007 Aug;4(8):1678-92
pubmed: 17712814
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Lancet Oncol. 2005 Jan;6(1):35-42
pubmed: 15629274
Br J Cancer. 2006 Jul 17;95(2):197-203
pubmed: 16804518
Neuro Oncol. 2009 Jun;11(3):330-9
pubmed: 19001097
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):285-91
pubmed: 23642624
Nat Rev Cancer. 2003 Oct;3(10):745-55
pubmed: 14570037
Br J Pharmacol. 2006 May;148(2):123-35
pubmed: 16501583
N Engl J Med. 1975 Oct 16;293(16):795-7
pubmed: 1099449
Lancet. 1980 May 31;1(8179):1187-8
pubmed: 6104004
Curr Oncol Rep. 2016 Jul;18(7):40
pubmed: 27215434